SCHEMBL4415737

SCHEMBL4415737

CC(C)(C)Oc1ccc(CN2CC3C(CNc4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 4/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH2 P05091 1/20 0.38
USP30 Q70CQ3 2/20 0.37
CYP2C9 P11712 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
LDHA P00338 1/20 0.36
LDHB P07195 1/20 0.36
ALOX15 P16050 2/20 0.36
MAPK1 P28482 1/20 0.36
ABL1 P00519 1/20 0.36
KCNH2 Q12809 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 1/20 0.36
HIF1A Q16665 1/20 0.36
EPAS1 Q99814 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411176 0.92 ABL1 (0.44) GAAALDH1A1MAPK1ABL1KCNH2
SCHEMBL4415239 0.90 SMN1; SMN2 (0.46) L3MBTL1KDM4EALDH2MAPK1HTT
SCHEMBL6506969 0.89 ALDH1A1 (0.50) L3MBTL1GAAALDH1A1KDM4EALDH2
SCHEMBL4420889 0.88 MAOB (0.45) P2RX3L3MBTL1GAAALDH1A1KDM4E
SCHEMBL4412123 0.87 L3MBTL1 (0.41) L3MBTL1GAAALDH1A1ALDH2USP30
SCHEMBL2170676 0.87 LMNA (0.44) L3MBTL1GAAALDH1A1ALDH2USP30
SCHEMBL4412370 0.87 L3MBTL1 (0.44) L3MBTL1GAAUSP30MAOAMAOB
SCHEMBL4413699 0.87 GAA (0.48) L3MBTL1GAAALDH1A1ALDH2USP30
SCHEMBL4413306 0.87 L3MBTL1 (0.49) L3MBTL1GAAALDH1A1KDM4EALDH2
SCHEMBL4423662 0.87 CNR2 (0.42) L3MBTL1GAAALDH1A1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 P2RX3 649/4885L3MBTL1 1416/4885GAA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.